caffeine has been researched along with Malignant Melanoma in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)." | 9.05 | Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980) |
| "Caffeine has been studied as a potentiating agent in chemotherapy against some types of cancer, but there are few reports on its effects on melanoma." | 8.12 | Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells. ( Bordini, HP; Cecchini, AL; Fagundes, TR; Luiz, RC; Madeira, TB; Marinello, PC; Melo, GP; Nixdorf, SL, 2022) |
| ", caffeine, using a cellular model of melanoma at a defined differentiation level." | 8.02 | Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches. ( Beninati, S; Bonaccio, M; Cordella, M; Eramo, A; Facchiano, A; Facchiano, F; Iacoviello, L; Mischiati, C; Rossi, S; Tabolacci, C, 2021) |
| "Increasing caffeine intake and caffeinated coffee consumption is associated with decreased risk of cutaneous malignant melanomas." | 7.81 | Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma. ( Cho, E; Gao, X; Han, J; Hunter, DJ; Qureshi, AA; Song, F; Wu, S, 2015) |
| "In the human melanoma cell line MM127 , the melphalan survival curve was linear and exhibited reciprocity with respect to concentration and treatment time." | 7.67 | Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. ( Parsons, PG, 1984) |
| "One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)." | 5.05 | Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980) |
| "Caffeine has been studied as a potentiating agent in chemotherapy against some types of cancer, but there are few reports on its effects on melanoma." | 4.12 | Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells. ( Bordini, HP; Cecchini, AL; Fagundes, TR; Luiz, RC; Madeira, TB; Marinello, PC; Melo, GP; Nixdorf, SL, 2022) |
| ", caffeine, using a cellular model of melanoma at a defined differentiation level." | 4.02 | Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches. ( Beninati, S; Bonaccio, M; Cordella, M; Eramo, A; Facchiano, A; Facchiano, F; Iacoviello, L; Mischiati, C; Rossi, S; Tabolacci, C, 2021) |
| "Increasing caffeine intake and caffeinated coffee consumption is associated with decreased risk of cutaneous malignant melanomas." | 3.81 | Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma. ( Cho, E; Gao, X; Han, J; Hunter, DJ; Qureshi, AA; Song, F; Wu, S, 2015) |
| "The aim of this study was to investigate the mechanism of pseudolaric acid B (PLAB)-induced cell cycle arrest in human melanoma SK-28 cells." | 3.75 | Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway. ( Jiang, LL; Meng, AG, 2009) |
| " We report here that inhibitors of both the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism convert mouse melanoma and human fibrosarcoma cells to a non invasive state by reducing the production of MMP-2, an enzyme required for the degradation of basement membranes." | 3.69 | Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. ( Martin, GR; Reich, R, 1996) |
| "Frequency and distribution of 5-fluorodeoxyuridine (5-FdU) plus caffeine-induced fragile sites on chromosomes of peripheral blood lymphocytes (PBL) from 10 patients with cutaneous melanoma were studied in comparison with 10 PBL samples from normal donors of corresponding sex and age." | 3.68 | Enhanced expression of 1p32 and 1p22 fragile sites in lymphocytes in cutaneous malignant melanomas. ( Chebotarev, AN; Demidov, LV; Kirichenko, OP; Kopnin, BP; Mukeria, AF; Sokova, OI, 1992) |
| "We have examined the effect of caffeine on the concomitant processes of the repair of potentially lethal damage (PLD) and the synthesis of X-ray-induced proteins in the human malignant melanoma cell line, Ul-Mel." | 3.68 | Effect of caffeine on the expression of a major X-ray induced protein in human tumor cells. ( Boothman, DA; Hughes, EN, 1991) |
| "In the human melanoma cell line MM127 , the melphalan survival curve was linear and exhibited reciprocity with respect to concentration and treatment time." | 3.67 | Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. ( Parsons, PG, 1984) |
| "The therapeutic usefulness of chlorpromazine (CPZ) and caffeine (CAF) in combination with selected nitrosoureas was investigated in mice bearing L1210 leukemia, Lewis lung carcinoma, and B16 melanoma." | 3.66 | Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. ( Dykes, DJ; Laster, WR; Rose, WC; Schabel, FM; Trader, MW, 1978) |
| "To determine the association between total, caffeinated and decaffeinated coffee consumption and melanoma risk a dose-response meta-analysis on prospective cohort studies were performed." | 2.58 | Caffeinated and decaffeinated coffee consumption and melanoma risk: a dose-response meta-analysis of prospective cohort studies. ( Godos, J; Lafranconi, A; Marranzano, M; Micek, A; Pajak, A, 2018) |
| " Dose-response relationship was assessed by restricted cubic spline." | 2.53 | Coffee consumption and the risk of cutaneous melanoma: a meta-analysis. ( Li, X; Wang, J; Zhang, D, 2016) |
| " In the dose-response analysis, the RR of MM was 0." | 2.53 | Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study. ( Cai, J; Liu, J; Shen, B; Shi, M, 2016) |
| "Cutaneous melanoma is the fifth most common cancer in the United States." | 1.42 | Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. ( Freedman, ND; Graubard, BI; Hollenbeck, AR; Loftfield, E; Mayne, ST; Shebl, FM; Sinha, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (26.67) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Maksoud, MS | 1 |
| El-Gamal, MI | 1 |
| Lee, BS | 1 |
| Gamal El-Din, MM | 1 |
| Jeon, HR | 1 |
| Kwon, D | 1 |
| Ammar, UM | 1 |
| Mersal, KI | 1 |
| Ali, EMH | 1 |
| Lee, KT | 1 |
| Yoo, KH | 1 |
| Han, DK | 1 |
| Lee, JK | 1 |
| Kim, G | 1 |
| Choi, HS | 1 |
| Kwon, YJ | 1 |
| Lee, KH | 1 |
| Oh, CH | 1 |
| Fagundes, TR | 1 |
| Madeira, TB | 1 |
| Melo, GP | 1 |
| Bordini, HP | 1 |
| Marinello, PC | 1 |
| Nixdorf, SL | 1 |
| Cecchini, AL | 1 |
| Luiz, RC | 1 |
| Yerragopu, AK | 1 |
| Vellapandian, C | 1 |
| Dong, Y | 1 |
| Wei, J | 1 |
| Yang, F | 1 |
| Qu, Y | 1 |
| Huang, J | 1 |
| Shi, D | 1 |
| Tej, GNVC | 1 |
| Neogi, K | 1 |
| Nayak, PK | 1 |
| Tabolacci, C | 1 |
| Cordella, M | 1 |
| Rossi, S | 1 |
| Bonaccio, M | 1 |
| Eramo, A | 1 |
| Mischiati, C | 1 |
| Beninati, S | 1 |
| Iacoviello, L | 1 |
| Facchiano, A | 1 |
| Facchiano, F | 1 |
| Micek, A | 1 |
| Godos, J | 1 |
| Lafranconi, A | 1 |
| Marranzano, M | 1 |
| Pajak, A | 1 |
| Wrześniok, D | 1 |
| Rzepka, Z | 1 |
| Respondek, M | 1 |
| Beberok, A | 1 |
| Rok, J | 1 |
| Szczepanik, K | 1 |
| Buszman, E | 1 |
| Opletalova, K | 1 |
| Bourillon, A | 1 |
| Yang, W | 1 |
| Pouvelle, C | 1 |
| Armier, J | 1 |
| Despras, E | 1 |
| Ludovic, M | 1 |
| Mateus, C | 1 |
| Robert, C | 1 |
| Kannouche, P | 1 |
| Soufir, N | 1 |
| Sarasin, A | 1 |
| Loftfield, E | 1 |
| Freedman, ND | 1 |
| Graubard, BI | 1 |
| Hollenbeck, AR | 1 |
| Shebl, FM | 1 |
| Mayne, ST | 1 |
| Sinha, R | 1 |
| Wu, S | 1 |
| Han, J | 1 |
| Song, F | 1 |
| Cho, E | 1 |
| Gao, X | 1 |
| Hunter, DJ | 1 |
| Qureshi, AA | 1 |
| Yew, YW | 1 |
| Lai, YC | 1 |
| Schwartz, RA | 1 |
| Wang, J | 1 |
| Li, X | 1 |
| Zhang, D | 1 |
| Liu, J | 1 |
| Shen, B | 1 |
| Shi, M | 1 |
| Cai, J | 1 |
| Meng, AG | 1 |
| Jiang, LL | 1 |
| Ravi, D | 1 |
| Muniyappa, H | 1 |
| Das, KC | 1 |
| Boon, MH | 1 |
| Parsons, PG | 2 |
| Cohen, MH | 1 |
| Schoenfeld, D | 1 |
| Wolter, J | 1 |
| Reich, R | 1 |
| Martin, GR | 1 |
| Darbon, JM | 1 |
| Penary, M | 1 |
| Escalas, N | 1 |
| Casagrande, F | 1 |
| Goubin-Gramatica, F | 1 |
| Baudouin, C | 1 |
| Ducommun, B | 1 |
| Zölzer, F | 1 |
| Streffer, C | 1 |
| Rose, WC | 1 |
| Trader, MW | 1 |
| Dykes, DJ | 1 |
| Laster, WR | 1 |
| Schabel, FM | 1 |
| Sokova, OI | 1 |
| Kirichenko, OP | 1 |
| Mukeria, AF | 1 |
| Demidov, LV | 1 |
| Chebotarev, AN | 1 |
| Kopnin, BP | 1 |
| Hughes, EN | 1 |
| Boothman, DA | 1 |
| Ishiguro, K | 1 |
| Ueda, K | 1 |
| Miyoshi, N | 1 |
| Nakanishi, K | 1 |
| Fukuda, M | 1 |
| Osieka, R | 2 |
| Glatte, P | 2 |
| Schmidt, CG | 2 |
| Pannenbäcker, R | 1 |
| Kreider, JW | 1 |
| Rosenthal, M | 1 |
| Lengle, N | 1 |
| Gaudin, D | 1 |
| Yielding, KL | 1 |
| Stabler, A | 1 |
| Brown, J | 1 |
5 reviews available for caffeine and Malignant Melanoma
| Article | Year |
|---|---|
Nutrient-Based Approaches for Melanoma: Prevention and Therapeutic Insights.
Topics: Caffeine; Diet; Flavonoids; Humans; Melanoma; Vitamin A; Vitamin D; Vitamins | 2023 |
Caffeinated and decaffeinated coffee consumption and melanoma risk: a dose-response meta-analysis of prospective cohort studies.
Topics: Caffeine; Coffee; Cohort Studies; Dose-Response Relationship, Drug; Humans; Melanoma; Prospective St | 2018 |
Coffee Consumption and Melanoma: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Caffeine; Chemoprevention; Chlorogenic Acid; Coffee; Diterpenes; Humans; Male; Melanoma; Observation | 2016 |
Coffee consumption and the risk of cutaneous melanoma: a meta-analysis.
Topics: Caffeine; Coffee; Dose-Response Relationship, Drug; Humans; Melanoma; Melanoma, Cutaneous Malignant; | 2016 |
Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study.
Topics: Caffeine; Coffee; Drinking Behavior; Humans; Melanoma; Risk Factors; Risk Reduction Behavior; Skin N | 2016 |
1 trial available for caffeine and Malignant Melanoma
| Article | Year |
|---|---|
Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
Topics: Caffeine; Chlorpromazine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Melanoma; Nit | 1980 |
24 other studies available for caffeine and Malignant Melanoma
| Article | Year |
|---|---|
Discovery of New Imidazo[2,1-
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Scr | 2021 |
Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caffeine; Cell Line, Tumor; Dacarbazine; Melanoma; Mice | 2022 |
Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors.
Topics: Adenosine; Animals; Caffeine; Doxorubicin; Immunogenic Cell Death; Melanoma; Mice; T-Lymphocytes; Tu | 2023 |
Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Caffeine; CD4-Positive T-Lymphocytes; CD8-Po | 2019 |
Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches.
Topics: Caffeine; Cell Differentiation; Cell Line, Tumor; Central Nervous System Stimulants; Computational B | 2021 |
Caffeine modulates growth and vitality of human melanotic COLO829 and amelanotic C32 melanoma cells: Preliminary findings.
Topics: Caffeine; Cell Line, Tumor; Cell Survival; Chemoprevention; Flow Cytometry; Homeostasis; Humans; Mel | 2018 |
Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cells, Cu | 2014 |
Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study.
Topics: Adult; Aged; Caffeine; Coffee; Feeding Behavior; Female; Humans; Incidence; Male; Melanoma; Melanoma | 2015 |
Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma.
Topics: Adult; Aged; Caffeine; Coffee; Cohort Studies; Diet; Female; Follow-Up Studies; Humans; Male; Melano | 2015 |
Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway.
Topics: Ataxia Telangiectasia Mutated Proteins; Caffeine; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycl | 2009 |
Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism.
Topics: Ataxia Telangiectasia Mutated Proteins; Caffeine; Casein Kinase II; Cell Cycle Proteins; Cell Line, | 2008 |
Cyclophosphamide resistance developed in a human melanoma cell line.
Topics: Benzamides; Caffeine; Cell Line; Cross-Linking Reagents; Cyclophosphamide; Drug Resistance; Humans; | 1984 |
Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines.
Topics: Caffeine; Cell Line; Cell Survival; Chlorambucil; DNA, Neoplasm; Drug Resistance; Drug Synergism; Ho | 1984 |
Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells.
Topics: Animals; Arachidonic Acid; Caffeine; Collagen; Cyclooxygenase Inhibitors; Dinoprost; Drug Combinatio | 1996 |
Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells.
Topics: Caffeine; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell Division; Checkpoint Kinase 2; C | 2000 |
G2-phase delays after irradiation and/or heat treatment as assessed by two-parameter flow cytometry.
Topics: Bromodeoxyuridine; Caffeine; Cell Cycle; Flow Cytometry; G2 Phase; Humans; Hyperthermia, Induced; Me | 2001 |
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
Topics: Animals; Caffeine; Carmustine; Chlorpromazine; Drug Synergism; Drug Therapy, Combination; Female; Le | 1978 |
Enhanced expression of 1p32 and 1p22 fragile sites in lymphocytes in cutaneous malignant melanomas.
Topics: Adult; Caffeine; Cells, Cultured; Chromosome Fragile Sites; Chromosome Fragility; Chromosomes, Human | 1992 |
Effect of caffeine on the expression of a major X-ray induced protein in human tumor cells.
Topics: Caffeine; Cell Line; DNA Repair; Humans; Melanoma; Protein Biosynthesis; Tumor Cells, Cultured | 1991 |
[A sensitization effect of hematoporphyrin oligomer (HpO) and caffeine for X-ray radiation of skin cancer].
Topics: Animals; Caffeine; Combined Modality Therapy; DNA Damage; DNA, Neoplasm; Hematoporphyrins; Humans; M | 1990 |
Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
Topics: Animals; Caffeine; Chlorpromazine; Drug Resistance; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Tra | 1989 |
Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caffeine; Chlorpromazine; DNA | 1986 |
Cyclic adenosine 3',5'-monophosphate in the control of melanoma cell replication and differentiation.
Topics: Caffeine; Cell Differentiation; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Cyc | 1973 |
The effect of DNA repair inhibitors on e response of tumors treated with x-ray and alkylating agents.
Topics: Alkylating Agents; Animals; Bone Marrow; Caffeine; Chloroquine; Cricetinae; Cyclophosphamide; DNA; L | 1971 |